首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 734 毫秒
1.
对生物可吸收聚(丙交酯-co-乙交酯)(poly(lactide-co-glycolide),PLGA)与β-磷酸三钙(-βTCP)复合物体系进行了电纺.研究了PLGA的浓度,-βTCP与PLGA比例,加料速度,电压,喷头与接收体之间的距离等因素对电纺过程的影响,制备出纳米纤维膜,并用扫描电镜(SEM)等对纤维膜进行表征.结果表明,电纺溶液浓度越高,或者加料速度越快,纳米纤维的直径越粗.力学实验显示,复合物中-βTCP的含量增加使纳米纤维膜的拉伸强度和杨氏模量下降.  相似文献   

2.
改性纳米羟基磷灰石/PLGA复合材料的制备及生物活性   总被引:2,自引:0,他引:2  
以低聚乳酸接枝改性的羟基磷灰石纳米粒子(op-HA)和聚丙交酯-乙交酯(PLGA)制备的生物可降解纳米复合材料(op-HA/PLGA)为研究对象, 采用FTIR, TGA, ESEM和EDX分析其接枝反应、接枝率、表面形貌和钙磷沉积情况, 通过在材料膜表面接种兔成骨细胞进行体外培养, 采用荧光染色、NIH Image J图像分析和Real-time PCR综合评价细胞在材料表面的形态、黏附面积比、增殖能力和基因表达水平, 以此评价新型骨修复纳米复合材料op-HA/PLGA的表面性质和生物活性. 研究结果表明, op-HA的表面接枝率为8.3%, 掺入至PLGA后可形成富含钙磷的粗糙表面, 促进成骨细胞的黏附、扩展和增殖, 提高Ⅰ型胶原蛋白(Collagen-Ⅰ)、骨形态蛋白-2(BMP-2)和骨连接蛋白(Osteonectin)的基因表达水平, 提高材料的钙磷沉积能力. op-HA/PLGA具有良好的细胞相容性和成骨活性.  相似文献   

3.
以丙交酯开环聚合原位接枝改性的纳米生物玻璃(PLLA-g-BG)与聚丙交酯-乙交酯(PLGA)复合材料为研究对象, 采用TGA, ESEM和EDX分析其接枝率, 粒子分散性和表面元素分布, 通过将兔成骨细胞种植于材料膜表面进行体外培养, 采用荧光染色法、NIH Image J图像分析软件、MTT法和流式细胞术等手段检测细胞在材料表面的平均黏附数量、扩展面积比、增殖能力和细胞周期的变化, 综合评价新型改性纳米复合材料的生物相容性和生物活性. 结果表明, 聚乳酸表面接枝改性可明显改善纳米生物玻璃粒子的团聚; PLGA中掺入一定比例的改性PLLA-g-BG可明显促进兔成骨细胞的黏附、扩展与增殖; 改性纳米生物玻璃的应用可提高生物可降解聚酯材料的生物相容性和生物活性.  相似文献   

4.
壳聚糖修饰PLGA阳离子型纳米微球的制备与表征   总被引:7,自引:1,他引:6  
采用单乳化-溶剂(O/W)挥发技术制备表面带正电荷的壳聚糖(CHS)修饰聚乙/丙交酯(PLGA)纳米微球(PLGA/CHS), 通过正交试验优化了纳米微球的制备条件. 结果表明, 微球粒径可控制在150~200 nm内, 在pH=4时, 纳米微球表面电位最高为55 mV. 影响微球粒径的主要因素是聚合物的浓度, CHS的分子量和浓度以及介质的pH值对微球表面电位也有明显影响. 制备粒径较小而表面电位较高的PLGA/CHS纳米微球条件为: ρ(CHS)=3 mg/mL, ρ(PLGA)=10 mg/mL, Vo/Va=1/4. SEM图像显示经CHS修饰的PLGA的纳米微球形状规整, 荧光显微观察和XPS分析结果证实CHS包覆于微球表面.  相似文献   

5.
分别以聚乙二醇(PEG)、聚(丙交酯-乙交酯)(PLGA)和牛血清白蛋白(BSA)为冠、壳和核层材料,采用三层同轴电喷技术制备得到微米颗粒.激光共聚焦显微镜(LSCM)显示,该方法制备得到的微米颗粒呈现核-壳-冠结构.通过脱去该微米颗粒的PEG冠层(模板),得到包载有BSA的纳米颗粒.研究发现,随着壳层PLGA溶液进样速度的减慢,去模板后纳米颗粒的粒径从约146 nm减小到68 nm.BSA在纳米颗粒中的包埋率可高达78.3%,并且其释放没有显著的药物暴释现象.圆二色谱结果表明,同轴电喷过程对BSA二级结构影响很小.因此,利用三层同轴电喷-去模板法可制备得到粒径可调控的蛋白质纳米载体系统,并且该过程中蛋白质的结构基本维持不变.  相似文献   

6.
合成了一种甘露醇引发的星型共聚物甘露醇-聚乳酸-聚乙三醇1000维生素E琥珀酸酯(M-PLATPGS).利用纳米沉淀法制备载紫杉醇M-PLA-TPGS纳米颗粒.纳米颗粒近似球形,粒径分布较窄.对载药纳米颗粒进行粒径、表面电荷、载药量、包封率和体外药物释放的表征,结果表明,体外药物释放呈双相释放模型,M-PLA-TPGS纳米颗粒在前列腺癌PC-3细胞中的摄取水平要高于PLGA和PLA-TPGS纳米颗粒.载紫杉醇M-PLA-TPGS纳米颗粒对于前列腺癌细胞的的毒性显著高于载紫杉醇PLA-TPGS纳米颗粒和商业制剂Taxol,证明星型M-PLA-TPGS聚合物作为纳米药物载体优于线性PLGA和PLA-TPGS聚合物.  相似文献   

7.
二元溶剂分散法制备PLA和PLGA纳米粒   总被引:4,自引:1,他引:3  
聚乳酸;聚丙交酯乙交酯;二元溶剂分散法制备PLA和PLGA纳米粒  相似文献   

8.
以钛酸四丁酯为前驱体,乙醇为溶剂,月桂酸和十二胺为共同稳定剂,采用溶剂热法制备了不同形状的锐钛矿型二氧化钛纳米晶。利用透射电子显微镜(TEM)、选区电子衍射(SAED)、X射线衍射(XRD)、傅里叶变换红外(FTIR)光谱和热失重-差热分析(TG-DTA)等技术对纳米晶的结构、尺寸、形貌及形状进行了系统的表征,并探讨了月桂酸与十二胺不同配比时纳米晶的形状演化规律。结果表明:用溶剂热法在不同配比情况下获得的二氧化钛均为锐钛矿相;在月桂酸与十二胺总摩尔量不变的情况下,随着十二胺含量的增加,二氧化钛纳米晶的形状由球形逐渐演化为棒状,且结晶化程度在两者摩尔比为1:1时最好;月桂酸与十二胺稳定剂与纳米晶内核之间以桥接配位体的形式结合,且稳定剂在样品中的含量约为5%。  相似文献   

9.
采用简单的溶液浇铸法制备了不同硒化镉-硫化锌核壳结构量子点(CdSe-ZnSQDs)含量的QDs/乳酸-乙醇酸共聚物(PLGA)纳米复合材料薄膜,对薄膜的微观结构、谱学性能等进行了系统的研究后,重点研究了PLGA、QDs/PLGA复合材料的体外降解行为.荧光光谱、紫外-可见光谱分析结果显示QDs与PLGA复合后仍具有稳定优异的发光性能和吸光度,且发光和吸光强度随QDs含量增加而增大.在体外降解的研究中,凝胶渗透色谱结果和磷酸盐缓冲液的pH值变化显示量子点的加入加快了PLGA的降解;而复合材料的荧光效应随着降解的进行而逐渐减弱.以上结果证明CdSe-ZnSQDs/PLGA纳米复合材料可采用简单的溶液浇铸法成功制备,且可通过检测荧光效应变化来监测QDs/PLGA复合材料的降解进程.  相似文献   

10.
采用十六烷基三甲基溴化铵为模板剂,钛酸正四丁酯为原料,水热法合成出孔径为4.4 nm介孔二氧化钛.通过X射线粉末衍射仪、透射电子显微镜和氮气吸附技术对样品进行了表征.以甲基橙为模型化合物,考察了铜(Ⅱ)对介孔二氧化钛光催化活性的影响,研究表明:介孔二氧化钛的光催化活性与P25纳米二氧化钛相当,铜(Ⅱ)的加入提高了介孔二氧化钛的光催化活性,甲基橙的光催化降解速率与光强度成正比.  相似文献   

11.
水包油包固体乳化法制备蛋白药物缓释微球   总被引:1,自引:0,他引:1  
以牛血清白蛋白(BSA)为模型药物, 研究了一种新型载药微球的水包油包固体(S/O/W)乳化法. 用纳米尺寸的SiO2吸附溶液中的BSA, 得到粒径约为30 nm的含药粒子, 再用PLGA包裹含药粒子. 考察不同制备条件对载药量和包封率的影响, 并与传统的双乳法(W/O/W)进行了对比, 发现该制备方法提高了药物的载药量(由2.5%到3.1%)和包封率(由72%到90%以上), 同时提高了药物活性.  相似文献   

12.
摘要 采用喷雾干燥法制备包载地塞米松(Dex)的聚L-丙交酯-b-聚乙二醇(PLLA-PEG)微球, 以热致相分离/粒子洗去法制备聚乙交酯-co-丙交酯(PLGA)多孔支架, 通过复合溶结法将载药微球固定于PLGA多孔支架中, 制得载药微球-支架(记为MS-S). 另外, 在支架制备过程中将Dex直接加入PLGA溶液中, 制得对比的直接载药支架(记为D-S). 以扫描电镜观察微球和支架的微观形貌, 在循环压应力与水浴摇床两种环境下分别对上述两种载药支架进行控制释放Dex的实验, 用紫外-可见光分光光度计测定Dex的累积释放量. 结果表明, Dex及微球的载入对PLGA支架的整体形貌影响较小; 循环压应力显著提高了Dex从载药支架中的释放速率, 与D-S相比, MS-S延缓了药物的释放. 研究模拟体内循环压应力下支架控制释放药物规律对于实现理想的临床效果具有重要意义.  相似文献   

13.
Preparation of PLGA microspheres with different porous morphologies   总被引:1,自引:0,他引:1  
甘志华  王峰 《高分子科学》2015,33(1):128-136
Poly(D,L-lactide-co-glycolide)(PLGA) microspheres were prepared by emulsion solvent evaporation method. The influences of inner aqueous phase, organic solvent, PLGA concentration on the morphology of microspheres were studied. The results showed that addition of porogen or surfactants to the inner aqueous phase, types of organic solvents and polymer concentration affected greatly the microsphere morphology. When dichloromethane was adopted as organic solvent, microspheres with porous structure were produced. When ethyl acetate served as organic solvent, two different morphologies were obtained. One was hollow microspheres with thin porous shell under a lower PLGA concentration, another was erythrocyte-like microspheres under a higher PLGA concentration. Three types of microspheres including porous, hollow core with thin porous shell(denoted by hollow in brief) and solid structures were finally selected for in vitro drug release tests. Bovine serum albumin(BSA) was chosen as model drug and encapsulated within the microspheres. The BSA encapsulation efficiency of porous, hollow and solid microspheres was respectively 90.4%, 79.8% and 0. And the ultimate accumulative release was respectively 74.5%, 58.9% and 0. The release rate of porous microspheres was much slower than that of hollow microspheres. The experiment results indicated that microspheres with different porous structures showed great potentials in controlling drug release behavior.  相似文献   

14.
The purpose of this study was to develop a suitable formulation for gentamicin sulfate (GS) that gives a sustained release of the drug. Therefore this drug was loaded into poly(D,L-lactide-co-glycolide) (PLGA) and poly(lactic-co-hydroxymethyl glycolic acid) (PLHMGA) microspheres. The effects of various formulation parameters (ethanol, surfactant, osmotic value of the external phase, polymer type and concentration) on particle characteristics (size, loading and release) were investigated. The GS loaded microspheres were prepared using a double emulsion evaporation technique. The results demonstrate that neither ethanol nor surfactants had beneficial effects on the drug loading efficiency (around 4-10%). However, an increase in buffer concentration (and thus osmotic pressure) of the external phase resulted in a substantial increase of GS-loading (from 10 to 28%). Further, an increase of concentration of PLGA in DCM from 10% to 15/20% caused a 4-time increase of the drug loading. The best formulation identified in this study had a loading efficiency of around 70% resulting in PLGA microspheres with a 6% (w/w) loading. The particles showed a burst release of the drug depending on their porosity, followed by a phase of 35 days where hardly any release occurred. The drug was then slowly released for around 25 days likely due to degradation of the microspheres. The drug loading efficiency of GS in PLHMGA was not significantly different from PLGA microspheres (64%). The release of GS from PLHMGA microspheres was faster than that of PLGA because the degradation rate of PLHMGA is more rapid than PLGA. This study shows that prolonged release of gentamicin can be obtained by loading this drug into microspheres made of biodegradable aliphatic polyesters.  相似文献   

15.
The entrapment of a protein in porous poly(d,l ‐lactide‐co‐glycolide) (PLGA) microspheres is demonstrated through the closure of their outer surface pores for sustained delivery of the protein. The porous PLGA microspheres with less than 10 μm in size are prepared by electrospraying. Aqueous solutions containing fluorescein isothiocyanate‐dextran or bovine serum albumin (BSA) are penetrated into the inner pores as a result of vacuum treatment, and the outer surface pores of the porous PLGA microspheres are then closed using a solvent (dimethyl sulfoxide) to ensure entrapment of the macromolecules. Confocal microscopy images confirm the presence of a large amount of the macromolecules inside the porous structure. Circular dichroism spectroscopy and release analysis reveal that BSA is entrapped without denaturation and released in a sustained manner for a period of over 2 months, respectively.

  相似文献   


16.
Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over‐expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti‐EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico‐chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti‐EGFR (BSA‐Gem‐EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA‐Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface. Copyright © 2012 John Wiley & Sons, Ltd.  相似文献   

17.
在离子液体均相体系中合成了一种新型两亲性窄分子量分布的低聚壳聚糖衍生物月桂基-琥珀酰化壳聚糖(LSCOS). 以LSCOS为载体材料, 以牛血清蛋白(BSA)为模板蛋白, 以戊二醛为交联剂, 用油包水(W/O)乳化交联法制备了包载BSA的BSA/LSCOS缓释载药微球. 通过扫描电子显微镜(SEM)、 透射电子显微镜(TEM)及紫外-可见光谱(UV-Vis)研究了BSA/LSCOS比率和戊二醛/LSCOS比率对微球的形貌结构、 包埋率、 载药率和体外药物释放特性的影响. 结果表明, 在离子液体中合成的LSCOS包覆了BSA, 形成的微球粒径约为1 μm, 微球表面随BSA用量的增加变得光滑, 随戊二醛用量的增加变得粗糙. BSA的累积释放率与BSA包载量成正比, 与交联剂添加量成反比, 因此, 可通过控制蛋白质药物的添加比率和交联剂用量来控制蛋白质药物体外释放率.  相似文献   

18.
In order to encapsulate and controlled-release bioactive proteins,three fibrous membranes,i.e.,poly(L-lactide-co-glycolide)(PLGA),hybrid PLGA and chitosan(H-PLGA/CS),and core/shell PLGA/CS (C-PLGA/CS),were produced by emulsion electrospinning,co-electrospinning and coaxial electrospinning,respectively.Bovine serum albumin(BSA) was selected as a model protein.The loading efficiency of BSA in the PLGA membrane was 1.56%,lower than those of H-PLGA/CS(5.98%) and C-PLGA/CS(4.80%).BSA release profiles from the th...  相似文献   

19.
Well-defined nitrogen-doped, hollow SiO2/TiO2 hybrid spheres were successfully prepared through a two-step sol-gel synthesis combined calcination process using triethylamine as the nitrogen source. In this approach, polystyrene (PS)/silica microspheres were first synthesized. Subsequently, the amine-treated PS/SiO2/TiO2 hybrid spheres were obtained by sol-gel method. Finally, the elimination of the PS core, nitrogen-doping process, and crystallization of amorphous TiO2 were simultaneously conducted in the calcination process to acquire the final products. The as-prepared hybrid spheres were characterized by scanning electron microscopy, transmission electron microscopy, X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), and Fourier transform infrared (FTIR) spectroscopy. The results of XRD, FTIR, and XPS spectra indicated that nitrogen was really doped into the anatase TiO2 shell and confirmed that most nitrogen dopants might be present in the chemical environments of N-Ti-O and Ti-N-O. It was found that the absorption shoulder of nitrogen-doped hollow SiO2/TiO2 hybrid spheres vastly shifted to the visible region up to around 530 nm. The photoluminescence (PL) bands showed spectral lines at about 421, 472, and 529 nm, which were attributed to the self-trapped excitons, F and F+ centers. Moreover, the intensity of the PL spectra band of hollow SiO2/TiO2 hybrid spheres increased with as the amount of titanium tetrabutoxide (TBOT) precursor increased. However, the doping of nitrogen into hollow SiO2/TiO2 hybrid spheres led to the drastic quenching of photoluminescence because of the increase in the separation efficiency of the photoinduced electron and hole pairs.  相似文献   

20.
A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing hormone-releasing hormone (LHRH) antagonists, LXT-101 was prepared and evaluated in the paper. LXT-101 microspheres were prepared from PLGA by three methods: (1) double-emulsion solvent extraction/evaporation technique, (2) single-emulsion solvent extraction/evaporation technique, and (3) S/O/O (solid-in-oil-in-oil) method. The microspheres were investigated on drug loading, particle size, surface morphology and in vitro release profiles. An accelerated release approach was also established in order to expedite the evaluation periods. The in vivo evaluation of the microspheres was made by monitoring testosterone levels after subcutaneous administration to rats. The LXT-101 PLGA microspheres showed smooth and round surfaces according to a scanning electron microscopic investigation, and average particle size of ca. 30 mum according to laser diffractometry. The drug encapsulation efficiency of microspheres was influenced by LA/GA ratio of PLGA, salt concentrations, solvent mixture and preparation methods. Moreover, LA/GA ratio of PLGA, different preparation methods and different peptide stabilizers affected in vitro release of drugs. In vivo study, the testosterone levels were suppressed to castration up to 42 d as for the 7.5 mg/kg dose. And in vivo performance of LXT-101 microspheres was dose-dependent. The weights of rat sexual organs decreased and histopathological appearance of testes had little changes after 4-month microspheres therapy. This also testified that LXT-101 sustained release microspheres could exert the efficacy to suppress the testosterone level to castration with little toxicity. In conclusion, the PLGA microspheres could be a well sustained release system for LXT-101.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号